Sannette Hall
Sr. FAS Quanterix
Seminars
Wednesday 15th April 2026
Closing the Neuroimmune Biomarker Gap: Measuring Disease Biology in Blood and CSF to Support Drug Development
2:10 pm
Neuroimmune drug development is advancing rapidly, but translating emerging biology into actionable clinical insights remains a major challenge.- Neuroimmune drug development is focused on microglial biology, peripheral immune engagement, and novel innate immune targets.
- Despite progress, many programs face a critical bottleneck: a lack of sensitive, quantitative biomarkers capable of translating emerging biology into actionable clinical readouts.
- Ultra‑sensitive biomarker detection enables measurement of low‑abundance neuroimmune signals in blood and CSF.
- Use of established biomarkers such as NfL and GFAP, alongside emerging, novel markers of microglial activation and inflammatory signaling, support mechanistic insight, pharmacodynamic assessment, and patient stratification across the drug development pipeline.
- Integrating fluid‑based biomarkers with spatial biology approaches provides a more complete view of neuroimmune mechanisms.
